Loading organizations...
120 Capital operates as a specialized venture fund dedicated to the life science and healthcare sectors. The firm deploys capital into enterprises developing groundbreaking solutions, focusing on companies that demonstrate robust scientific foundations and the potential for significant market impact. Its approach combines strategic investment with deep industry insight to foster growth.
The fund's strategic direction is shaped by its key leadership, including Global Managing Director and CEO Leon Chen, Senior Managing Director Hannes Smárason, and Managing Director Colin Wang. With over a decade of operational experience, the firm was established on the insight that supporting innovative science and entrepreneurial vision is paramount to advancing healthcare frontiers.
120 Capital partners with emerging life science and healthcare companies, providing essential financial backing and expert guidance. The firm's vision centers on cultivating extraordinary companies that address unmet medical needs and drive progress in health outcomes globally. It seeks to realize the long-term potential of scientific discoveries through targeted investment.
120 Capital has 1 tracked investment across 1 company. The latest tracked deal is $58.0M Series B in Immunitas Therapeutics in August 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 1, 2021 | Immunitas Therapeutics | $58.0M Series B | Agent Capital | Alta Partners, Cofounders Capital, Domain Associates, Leaps BY Bayer, Longwood Fund, Novartis Venture Fund, Providence Ventures, RA Capital, Section 32, Netalie Nadivi, Alexandria Venture Investments, Evotec, Brian Halak, Mirae Asset, M Ventures, Novartis, NS Investment, ONO Venture Investment, Solasta Ventures, The Leukemia & Lymphoma Society, The Mark Foundation For Cancer Research |
